The DOI matches its Crossref record.
The Relationship of Antiphospholipid Antibodies to Thromboembolic Disease in Systemic Lupus Erythematosus: A Cross-Sectional Study
Abstract
In order to determine whether an association exists between antiphospholipid antibodies (APLA) and thromboembolic events in patients with systemic lupus erythematosus (SLE), we performed a cross-sectional study of consecutive unselected SLE patients. The occurrence of previous thromboembolic events was determined by investigators blinded to the APLA status of the patients by critical review of objective tests that had been performed at the time of symptomatic presentation and by performing venous Doppler ultrasound of the legs to elicit venous reflux as an indication of previous venous thrombosis. The presence of APLA was determined by coagulation assays for the lupus anticoagulant (LA) using five tests with well-defined control ranges and by ELISA assay for anticardiolipin antibodies (ACLA). These tests were measured on two separate occasions. The results of the study demonstrate a statistically significant association between persistently abnormal ACLA assays and thromboembolic events and a non-significant trend between persistently abnormal LA and thromboembolic events. Transient abnormalities of LA and ACLA were less strongly associated with thromboembolic events. We conclude that in patients with SLE, there is a significant association between thromboembolism and APLA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Even in the absence of antiphospholipid antibodies, patients with SLE have an increased risk of thromboembolic events.3”
From Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus (2020) · cites this paper as [3]
Citations
Cited by
Sorted by citations
Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy
Bates, S. M., Greer, I. A., Pabinger, I., Sofaer, S., & Hirsh, J. (2008) · CHEST Journal · doi:10.1378/chest.08-0761 · Cited by 790
Self-citationUse of Antithrombotic Agents During Pregnancy
Ginsberg, J. S., & Hirsh, J. (1995) · CHEST Journal · doi:10.1378/chest.108.4_supplement.305s · Cited by 660
Self-citationUse of Antithrombotic Agents During Pregnancy
Bates, S. M., Greer, I. A., Hirsh, J., & Ginsberg, J. S. (2004) · CHEST Journal · doi:10.1378/chest.126.3_suppl.627s · Cited by 550
Self-citationSchulman, S., Svenungsson, E., & Granqvist, S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00060-6 · Cited by 497
Management of Antiphospholipid Antibody Syndrome
Lim, W., Crowther, M. A., & Eikelboom, J. W. (2006) · JAMA · doi:10.1001/jama.295.9.1050 · Cited by 441
“Depending on the assay, antiphospholipid antibodies are reported in up to 10% of healthy individuals and in 30% to 50% of patients with SLE.(6) Antiphospholipid antibodies are more common in patients with thrombosis but a causal association is unproven and the clinical relevance of transient or low titer antiphospholi…”
BackgroundInfluentialFinazzi, G., Brancaccio, V., Moia, M., Ciavarella, N., Mazzucconi, M. G., Schinco, P., Ruggeri, M., Pogliani, E. M., Gamba, G., Rossi, E., et al. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00060-5 · Cited by 427
Antiphospholipid Antibodies and venous thromboembolism
Ginsberg, J., Wells, P., Brill-Edwards, P., Donovan, D., Moffatt, K., Johnston, M., Stevens, P., & Hirsh, J. (1995) · Blood · doi:10.1182/blood.v86.10.3685.bloodjournal86103685 · Cited by 365
Use of Antithrombotic Agents During Pregnancy
Ginsberg, J., Greer, I., & Hirsh, J. (2001) · CHEST Journal · doi:10.1378/chest.119.1_suppl.122s · Cited by 283
Self-citationMoroni, G. L., Ventura, D., Riva, P., Panzeri, P., Quaglini, S., Banfi, G., Simonini, P., Bader, R., Meroni, P. L., & Ponticelli, C. E. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2003.09.011 · Cited by 153
Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus
Denburg, S. D., Carbotte, R. M., & Denburg, J. A. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370907 · Cited by 145
Self-citationThromboembolism in paediatric lupus patients
Levy, D. M., Massicotte, M. P., Harvey, E. A., et al. (2003) · Lupus · doi:10.1191/0961203303lu458oa · Cited by 112
Berube, C., Mitchell, L. G., Silverman, E. D., David, M., Saint‐Cyr, C., Laxer, R. M., Adams, M., Vegh, P., & Andrew, M. E. (1998) · Pediatric Research · doi:10.1203/00006450-199809000-00014 · Cited by 108
Self-citationMale, C., Foulon, D., Hoogendoorn, H., Vegh, P., Silverman, E., David, M., & Mitchell, L. (2005) · Blood · doi:10.1182/blood-2005-05-2048 · Cited by 106
“However, there was no consistent association between a specific APLA subtype or isotype and either an arterial or venous TE.”
BackgroundResultInfluentialThrombophilia in pregnancy: Table 1
Walker, I. D. (2000) · Journal of Clinical Pathology · doi:10.1136/jcp.53.8.573 · Cited by 102
Use of Antithrombotic Agents During Pregnancy
Ginsberg, J. S., & Hirsh, J. (1998) · CHEST Journal · doi:10.1378/chest.114.5_supplement.524s · Cited by 101
Self-citationThe natural history and epidemiology of venous thrombosis
Carter, C. J. (1994) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(94)80051-0 · Cited by 98
Petri, M. (2020) · Translational research · doi:10.1016/j.trsl.2020.04.006 · Cited by 113
Escalante, A., Brey, R. L., Mitchell, B. D., & Dreiner, U. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80014-x · Cited by 95
Ginsberg, J., Brill-Edwards, P. A., Johnston, M., Denburg, J. A., Andrew, M., Burrows, R. F., Bensen, W., Cividino, A. A., & Long, A. A. (1992) · Blood · doi:10.1182/blood.v80.4.975.975 · Cited by 93
Self-citationThe Role of Thrombophilia in Pregnancy
Battinelli, E. M., Marshall, A. L., & Connors, J. M. (2013) · Thrombosis · doi:10.1155/2013/516420 · Cited by 88
Gezer, S. (2003) · Disease-a-Month · doi:10.1016/j.disamonth.2003.10.001 · Cited by 81
Which are the Best Biological Markers of the Antiphospholipid Syndrome?
Carreras, L. O., Forastiero, R. R., & Martinuzzo, M. E. (2000) · Journal of Autoimmunity · doi:10.1006/jaut.2000.0401 · Cited by 78
Thrombosis in systemic lupus erythematosus: Congenital and acquired risk factors
Afeltra, A., Vadacca, M., Conti, L., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21172 · Cited by 77
Ginsberg, J., Demers, C., Brill-Edwards, P. A., et al. (1993) · Blood · doi:10.1182/blood.v81.11.2958.2958 · Cited by 78
Self-citationMale, C., Mitchell, L. G., Julian, J. A., et al. (2001) · Blood · doi:10.1182/blood.v97.4.844 · Cited by 77
Self-citationGinsberg, J. S., Demers, C., Brill-Edwards, P. A., et al. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80317-9 · Cited by 77
Self-citationConformationally altered β2-glycoprotein I is the antigen for anti-cardiolipin autoantibodies
Chamley, L., Duncalf, A. M., Konarkowska, B., et al. (1999) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1999.00810.x · Cited by 72
Coagulation disorders in pregnancy: acquired and inherited thrombophilias
Benedetto, C., Marozio, L., Tavella, A. M., Salton, L., Grivon, S., & Giampaolo, F. D. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05674.x · Cited by 68
ANTIPHOSPHOLIPID ANTIBODY SYNDROME
Lockshin, M. D. (1994) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(21)00225-8 · Cited by 67
Parke, A. L., Weinstein, R. E., Bona, R., et al. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90679-6 · Cited by 69
Ferro, D., Pittoni, V., Quintarelli, C., Basili, S., Saliola, M., Caroselli, C., Valesini, G., & Violi, F. (1997) · Circulation · doi:10.1161/01.cir.95.6.1425 · Cited by 63
Tincani, A., Bazzani, C., Zingarelli, S., & Lojacono, A. (2008) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0028-1082270 · Cited by 58
WHICH PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODY SHOULD BE TREATED AND HOW?
Lockshin, M. D. (1993) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(21)00179-4 · Cited by 56
Anderson, J. A. M., & Weitz, J. I. (2011) · Critical Care Clinics · doi:10.1016/j.ccc.2011.09.007 · Cited by 67
Use of Antithrombotic Agents During Pregnancy
Ginsberg, J. S., & Hirsh, J. (1992) · CHEST Journal · doi:10.1378/chest.102.4_supplement.385s · Cited by 51
Self-citationSex and gender issues and venous thromboembolism
Moores, L. K., Bilello, K. L., & Murin, S. (2004) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2004.01.013 · Cited by 47
Martini, F., Farsi, A., Gori, A. M., et al. (1996) · Lupus · doi:10.1177/096120339600500307 · Cited by 49
Le, D., Griffin, J. H., Greengard, J. S., Mujumdar, V. S., & Rapaport, S. (1995) · Blood · doi:10.1182/blood.v85.7.1704.bloodjournal8571704 · Cited by 49
Anderson, J. A. M., & Weitz, J. I. (2010) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2010.07.004 · Cited by 46
Increased Anti-Phospholipid Antibodies in Autism Spectrum Disorders
Careaga, M., Hansen, R. L., Hertz-Piccotto, I., de Water, J. V., & Ashwood, P. (2013) · Mediators of Inflammation · doi:10.1155/2013/935608 · Cited by 44
“They are found in roughly ten percent of the population [10, 11] but are thought to cause pathology in only a small segment of those with antibodies.”
BackgroundCerebral microemboli in patients with antiphospholipid syndrome
Specker, C., Rademacher, J., Söhngen, D., et al. (1997) · Lupus · doi:10.1177/096120339700600804 · Cited by 43
Domingues, V., Magder, L. S., & Petri, M. (2016) · Lupus Science & Medicine · doi:10.1136/lupus-2015-000107 · Cited by 36
Hasbani, G. E., Viola, M., Sciascia, S., Taher, A. T., & Uthman, I. W. (2021) · Rheumatology and Therapy · doi:10.1007/s40744-020-00273-w · Cited by 35
Kwiecinski, J. M., Kłak, M., Trysberg, E., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24603 · Cited by 34
Antiphospholipid antibiodies: a critical review of the literature
Lim, W., & Crowther, M. A. (2007) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3282a4a65f · Cited by 32
Inhibitors to clotting factors
Sallah, S. (1997) · Annals of Hematology · doi:10.1007/s002770050305 · Cited by 32
Nervous System Lupus: Pathogenesis and Rationale for Therapy
Denburg, J. A., Denburg, S. D., Carbotte, R. M., Šaki, B., & Szechtman, H. (1995) · Scandinavian Journal of Rheumatology · doi:10.3109/03009749509095161 · Cited by 30
Self-citationFeinstein, D. (1992) · Blood · doi:10.1182/blood.v80.4.859.859 · Cited by 31
Yamamoto, K., & Loskutoff, D. J. (1997) · PubMed · Cited by 30
Battinelli, E. M., & Bauer, K. A. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.02.003 · Cited by 29
Habe, K., Wada, H., Matsumoto, T., Ohishi, K., Ikejiri, M., Matsubara, K., Morioka, T., Kamimoto, Y., Ikeda, T., Katayama, N., et al. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.5536 · Cited by 26
“The frequency of aPLs is reported to be 20-50% in patients with SLE (12-14), which is slightly higher than that seen in those with systemic scleroderma (SSc) (15, 16), Sjögren’s syndrome (SjS) (17) and/or rheumatoid arthritis (RA) (18, 19).”
BackgroundChamley, L. (1997) · Journal of Reproductive Immunology · doi:10.1016/s0165-0378(97)00063-6 · Cited by 24
A re‐appraisal of the normal cut‐off assignment for anticardiolipin IgM tests
Budd, R. C., HARLEY, E., Quarshie, A., Henderson, V. J., Harris, E. N., & Pierangeli, S. S. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02134.x · Cited by 23
Overview and assessment of risk factors for pulmonary embolism
Hoo, G. W. S. (2013) · Expert Review of Respiratory Medicine · doi:10.1586/ers.13.7 · Cited by 21
How to Identify High-Risk APS Patients: Clinical Utility and Predictive Values of Validated Scores
Oku, K., Amengual, O., Yasuda, S., & Atsumi, T. (2017) · Current Rheumatology Reports · doi:10.1007/s11926-017-0674-4 · Cited by 22
“Zuily et al., from the result of the prospective multi-centre study, reported that aPS/PT IgG was also significantly predictive of thrombosis in SLE patients [48].”
BackgroundInfluentialLoss of antiphospholipid antibody positivity post-thrombosis in SLE
Khawaja, M., Magder, L. S., GOLDMAN, D. W., & Petri, M. (2020) · Lupus Science & Medicine · doi:10.1136/lupus-2020-000423 · Cited by 22
Activation of human platelets by immune complexes prepared with cationized human IgG
Schattner, M. A., Lazzari, M., Trevani, A., et al. (1993) · Blood · doi:10.1182/blood.v82.10.3045.3045 · Cited by 22
de Godoy, J. M. P., de Godoy, M. F., & Braile, D. M. (2006) · Angiology · doi:10.1177/000331970605700111 · Cited by 23
Management of Antiphospholipid Antibody Syndrome
Lim, W., & Crowther, M. A. (2008) · Wiley eBooks · doi:10.1002/9781444300857.ch21 · Cited by 21
Chiou, Y.-M., Lan, J.-L., Hsieh, T.-Y., et al. (2005) · Lupus · doi:10.1191/0961203305lu2046cr · Cited by 20
Clinical Trials on Antiphospholipid Syndrome: What is Being Done and What is Needed?
Barbui, T., & Finazzi, G. (1994) · Lupus · doi:10.1177/096120339400300419 · Cited by 21
Parkpian, V., Verasertniyom, O., Vanichapuntu, M., et al. (2007) · Clinical Rheumatology · doi:10.1007/s10067-007-0566-5 · Cited by 17
Risk Factors for Antiphospholipid Antibodies and Antiphospholipid Syndrome
Aguirre-del-Pino, R., Monahan, R. C., Huizinga, T. W. J., Eikenboom, J. C. J., & Steup‐Beekman, G. M. (2024) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0043-1776910 · Cited by 21
Bijsterveld, N. R., Middeldorp, S., Berends, F., & Buller, H. R. (2000) · Journal of Thrombosis and Thrombolysis · doi:10.1023/a:1018722829498 · Cited by 16
“Lupus anticoagulant was ~rst described in patients with systemic lupus erythemathosus (SLE), although its occurrence is not limited to this disease [1,2].”
BackgroundCardiovascular events in patients with antiphospholipid antibodies: Strategies of prevention
Tufano, A., Guida, A., Minno, M. N. D. D., Gregorio, A. M. D., Cerbone, A. M., & Minno, G. D. (2010) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.10.016 · Cited by 14
Futrell, N., & Millikan, C. H. (1996) · Disease-a-Month · doi:10.1016/s0011-5029(96)90003-6 · Cited by 13
Thromboprophylaxis in Non-Surgical Patients:Who, When and How?
Gallus, A. S., Nurmohammed, M., Kearon, C., & Prins, M. H. (1998) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000022408 · Cited by 13
Management of women with systemic lupus erythematosus
Chugh, P. K. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.03.019 · Cited by 13
Orinda, G. O., Commins, M. A., Waltisbuhl, D. J., Goodger, B. V., & Wright, I. G. (1994) · Veterinary Immunology and Immunopathology · doi:10.1016/0165-2427(94)90025-6 · Cited by 12
Vayá, A., Santaolaria, M., Micó, L., Calvo, J., Oropesa, R., Villa, P., Todolí, J., Simó, M., Corella, D., & Ricart, J. M. (2008) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-2008-1117 · Cited by 10
“The association of acquired risk factors such as APAs (both ACAs and LA) with thrombotic events has been established by several authors [3–5,12, 18–”
Cardiovascular disease and antiphospholipid syndrome: how to predict and how to treat?
Calcaterra, I. L., Tufano, A., Lupoli, R., Iannuzzo, G., Emmi, G., & Minno, M. N. D. D. (2020) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15415 · Cited by 12
Antiphospholipid antibodies in critical illness
Dentali, F., & Crowther, M. A. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181c9e363 · Cited by 11
“APLA are present in 30% to 50% of patients with SLE (31, 32).”
BackgroundIschemic colitis, systemic lupus erythematosus, and the lupus anticoagulant: case report and review
Richardson, S. C., Willis, J. E., & Wong, R. C. K. (2003) · Gastrointestinal Endoscopy · doi:10.1067/mge.2003.51 · Cited by 11
Diagnosis and Management of Patients with the Antiphospholipid Syndrome
Alving, B. M. (2001) · Journal of Thrombosis and Thrombolysis · doi:10.1023/a:1012798713607 · Cited by 10
“Additional prospective [5] and retrospective [6] analyses have found that LA and ACA antibodies are detectable in approximately 50% of patients with SLE.”
BackgroundHirsh, J., Bates, S. M., Greer, I. A., Pabinger, I., & Sofaer, S. (2008) · Cited by 10
Self-citationNeville, C., Rauch, J., Kassis, J., Solymoss, S., Joseph, L., Bélisle, P., Subang, R., Chang, E. R., & Fortin, P. R. (2006) · Rheumatology · doi:10.1093/rheumatology/kel050 · Cited by 8
Zanon, E., Saracino, M. A., Simioni, P., et al. (1996) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/107602969600200114 · Cited by 8
“It is known that APA titers may fluctuate in time (31), and lower titers of APA are often tran-”
BackgroundAntiphospholipid-Protein Antibodies
Triplett, D. A. (1998) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.9.159 · Cited by 8
Venöse Thrombose in der Schwangerschaft
Gerhardt, A., Scharf, R. E., & Zotz, R. B. (2006) · Hämostaseologie · doi:10.1055/s-0037-1616881 · Cited by 7
“Venöse Thrombosen treten im Verlauf der Schwangerschaft bevorzugt auf der linken Seite auf.”
BackgroundInfluentialUse of Antithrombotic Agents During Pregnancy
Ginsberg, J. S., & Hirsh, J. (1993) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199306000-00004 · Cited by 7
Self-citationPetri, M. A., Avci, M., & Magder, L. S. (2020) · Lupus Science & Medicine · doi:10.1136/lupus-2020-000406 · Cited by 7
Expression of public idiotypes in patients with Lyme arthritis.
Axford, J. S., Watts, R. A., Long, A. A., et al. (1993) · Annals of the Rheumatic Diseases · doi:10.1136/ard.52.3.199 · Cited by 6
Self-citationBates, S. M., Ginsberg, J. S., Straus, S. E., Rekers, H., & Sackett, D. L. (2000) · Europe PMC (PubMed Central) · Cited by 5
Self-citationThrombophilia: how far should a clotter be investigated?
Walker, I. D. (1994) · Postgraduate Medical Journal · doi:10.1136/pgmj.70.824.411 · Cited by 4
The Antiphospholipid Syndrome: Clinical Presentation, Diagnosis, and Patient Management
Rand, J. H., Levin, M. B., & Alving, B. M. (2007) · Elsevier eBooks · doi:10.1016/b978-141602401-9.10019-7 · Cited by 4
Antı-β2 Glycoprotein I Antibodies in Children with Rheumatologic Disorders
Azarsız, E., Eman, G., Akarcan, S. E., et al. (2017) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-017-0711-0 · Cited by 3
Kaushik, P., MALAVIYA, A. N., Al-Attiya, R., Moussa, M. A. A., & Das, K. C. (1999) · Medical Principles and Practice · doi:10.1159/000026110 · Cited by 3
Rand, J. H., & Wolgast, L. R. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2296-9.00020-8 · Cited by 3
Hypercoagulable states: A concise review
Stawicki, S. P., & Prosciak, M. P. (2017) · International Journal of Academic Medicine · doi:10.4103/ijam.ijam_18_17 · Cited by 3
“It should also be recognized that most patients with LA do not have lupus erythematosus or other systemic autoimmune disorders.[10]”
BackgroundCourse and Prognosis of the Antiphospholipid Syndrome
Drenkard, C., & Alarcón-Segovia, D. (2002) · Elsevier eBooks · doi:10.1016/b978-044450987-1/50037-1 · Cited by 3
Epitope Mapping Studies of Antiphospholipid Antibodies and β 2 -GPI Using Synthetic Peptides
Kandiah, D. A., Je, H., & Krilis, S. (1995) · Lupus · doi:10.1177/096120339400400103 · Cited by 3
Takeno, M. R., & Gunn, J. B. (2015) · American Journal of BioMedicine · doi:10.18081/2333-5106/015-2/439-450 · Cited by 2
Die Patientin mit thrombophiler Blutgerinnungsstörung
Zotz, R. B., & Gerhardt, A. (2013) · Springer eBooks · doi:10.1007/978-3-642-38023-5_16 · Cited by 2
Low molecular weight heparins in pregnancy
Hoppensteadt, D. A., Fareed, J., Messmore, H. L., et al. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511526978.012 · Cited by 2
Clinical implications of laboratory testing for the thrombophilic disorders
Kirkland, M. A., & Gallus, A. S. (1993) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1993.tb01735.x · Cited by 2
Bates, S. M. (2016) · CRC Press eBooks · doi:10.3109/9781420069242-17 · Cited by 2
Thromboembolic Disease in Pregnancy
Bilodeau, C. C., & Rosene‐Montella, K. (2019) · doi:10.1002/9781119409861.ch22 · Cited by 2
Bartholomew, J. R. (2012) · Springer eBooks · doi:10.1007/978-1-4614-2203-7_9 · Cited by 1
“reported that approximately one-third of patients with SLE have aPL, while Long and Bruce states this number may be as high as 50% [ 7, 25, 26 ] .”
BackgroundThe scoring system for the risk-stratification in patients with the antiphospholipid syndrome
Oku, K. (2017) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.40.435 · Cited by 1
Antiphospholipid Syndrome in the Older Population
Pierangeli, S. S., Seif, A. M., & González, E. B. (2011) · Springer eBooks · doi:10.1007/978-1-4419-5792-4_24 · Cited by 1
Metadata
- Authors
- Long, A. A., Ginsberg, J. S., Brill-Edwards, P., Johnston, M., Turner, C., Denburg, J. A., Bensen, W. G., Cividino, A., Andrew, M., & Hirsh, J.
- Affiliations
- McMaster University (CA)
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 1991
- Volume
- 66
- Issue
- 05
- Pages
- 520-524
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2462341569
- Cited by
- 120
- References
- 0
- Citations by year
- 2026: 1 · 2024: 2 · 2021: 1 · 2020: 4 · 2019: 2 · 2018: 1 · 2017: 4 · 2016: 3 · 2015: 1 · 2013: 7 · 2012: 2
- FWCI
- 6.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Thrombosis and Haemostasis (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- antiphospholipid antibodies, systemic lupus erythematosus, thromboembolism, lupus anticoagulant, anticardiolipin antibodies, venous thrombosis, venous Doppler ultrasound, thrombosis risk factors
- MeSH terms
- Autoantibodies, Blood Coagulation Tests, Humans, Lupus Erythematosus, Systemic, Partial Thromboplastin Time, Phospholipids, Thromboembolism, Factor Xa
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
